Therefore, the potential application of IL-17E in treating kidney diseases, particularly in mitigating kidney injury caused by IRI, drug toxicity, or obesity, warrants further clinical research and exploration (Fig. 3E and Fig. S7). Here, IL25 is linked to obesity disorder.